Bromide

Bromide

SCHEMBL447562

CC[n+]1csc(CCO)c1C.[Br-]

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TKT P29401 15/20 0.52
HSP90AA1 P07900 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026240 0.98 TKT (0.54) TKTHSP90AA1
Iodide SCHEMBL1779438 0.96 TKT (0.52) TKTHSP90AA1
Hydrochloric Acid SCHEMBL7760396 0.96 TKT (0.52) TKTHSP90AA1
Sulfuric Acid SCHEMBL17102694 0.89 TKT (0.47) TKTHSP90AA1
Bromide SCHEMBL8941023 0.87 TKT (0.54) TKTHSP90AA1
Albitiazolium SCHEMBL2017697 0.82 TKT (0.50) TKTHSP90AA1
Bromide SCHEMBL5627875 0.80 TKT (0.52) TKTHSP90AA1
Bromide SCHEMBL3844686 0.80 TKT (0.50) TKTHSP90AA1
Bromide SCHEMBL3853203 0.80 TKT (0.48) TKTHSP90AA1
Bromide SCHEMBL10841344 0.79 TKT (0.45) TKTHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119701994-A Ferromanganese-based catalyst for preparing methyl methacrylate and preparation and application thereof 中国科学院大连化学物理研究所 2025-03-28 CN claimed
CN-116789577-A Preparation method of mesotrione compounds 北京颖泰嘉和生物科技股份有限公司 2023-09-22 CN claimed
CN-115116751-B Aluminum electrolytic capacitor electrolyte, preparation method thereof and aluminum electrolytic capacitor 深圳市新中元电子有限公司 2023-03-21 CN claimed
EP-3906235-B1 METHOD FOR PREPARING SULFONAMIDES DRUGS ASCENTAGE PHARMA SUZHOU CO LTD (CN) 2023-03-15 EP claimed
CN-115116751-A Aluminum electrolytic capacitor electrolyte, preparation method thereof and aluminum electrolytic capacitor 深圳市新中元电子有限公司 2022-09-27 CN claimed
US-11414400-B2 Method for preparing sulfonamides drugs ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2022-08-16 US claimed
CN-114031564-A 13, 14-picene quinoxaline and 13, 14-picene diazole derivatives and preparation method thereof 华东师范大学 2022-02-11 CN claimed
US-20210221788-A1 METHOD FOR PREPARING SULFONAMIDES DRUGS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2021-07-22 US claimed
CN-111410650-B Process for the preparation of sulfonamides 苏州亚盛药业有限公司 2020-12-08 CN claimed
CN-111533655-A Preparation method of long-carbon-chain keto dicarboxylic ester 广东工业大学 2020-08-14 CN claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0402151-B1 New 2, 5-diaryl tetrahydrofurans and analogs thereof as paf antagonists MERCK & CO INC (US) 1996-02-07 EP claimed
EP-0615854-A1 Recording sheets containing cationic sulphur compounds XEROX CORPORATION (US) 1994-09-21 EP claimed
EP-0330172-B1 Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis WARNER LAMBERT CO (US) 1994-08-10 EP claimed
US-5314747-A Recording sheets containing cationic sulfur compounds XEROX CORPORATION (US) 1994-05-24 US claimed
US-5216174-A Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis WARNER-LAMBERT CO. (US) 1993-06-01 US claimed
EP-0448552-A1 IMPROVED PROCESS FOR $i(TRANS)-6- 2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER-LAMBERT COMPANY (US) 1991-10-02 EP claimed
EP-0330172-A2 Improved process for trans-6-[2-(substituted-pyrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis WARNER-LAMBERT COMPANY (US) 1989-08-30 EP claimed
WO-1989007598-A2 IMPROVED PROCESS FOR TRANS-6-[2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER-LAMBERT COMPANY (US) 1989-08-24 WO claimed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11414400-B2 Method for preparing sulfonamides drugs BCL2, BCL3, BAK1 TKT 4092/4885HSP90AA1 2035/4885
US-20210221788-A1 METHOD FOR PREPARING SULFONAMIDES DRUGS BCL2, BCL3, BAK1 TKT 4092/4885HSP90AA1 2035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.